Risk for second primary cancer higher in patients who smoked prior to first cancer
the ONA take:
A significant behavior that increases the risk of developing cancer is cigarette smoking. This fact has been proven in countless studies, and a recent pooled analysis of five prospective cohort studies indicates that the cancer risk goes beyond developing a first primary cancer.
The analysis shows that patients who smoked 20 or more cigarettes a day prior to a diagnosis of lung (stage I), bladder, kidney, or head and neck cancer were at increased risk of developing a second primary smoking-associated cancer compared with patients who had never smoked and had survived the same first cancers. The researchers note the second primary cancers are not metastases of the first cancer, but distinct new malignancies.
Smokers who smoked fewer than 20 cigarettes per day and former smokers who had quit before their first cancer diagnosis also were at higher risk of developing a second cancer. This is the first study to explore the risk of second primary cancers in current smokers.
Although further research is needed to assess the association between smoking after a first cancer and second cancer risk, these results further support encouraging smoking cessation to all patients who smoke.
A significant behavior that increases the risk of developing cancer is cigarette smoking.
Results of a federally-funded pooled analysis of five prospective cohort studies indicate that cigarette smoking prior to the first diagnosis of lung (stage I), bladder, kidney or head and neck cancer increases risk of developing a second smoking-associated cancer. This is the largest study to date exploring risk of second cancers among current smokers.
An analysis of five large, prospective cohort studies indicates that lung (stage I), bladder, kidney and head and neck cancer survivors who smoked 20 or more cigarettes a day prior to their cancer diagnoses have an up to five-fold higher risk of developing a second smoking-associated cancer compared to survivors of the same cancers who never smoked.
- Cholesterol-Lowering Drugs May Prevent Breast Cancer Recurrence
- Idelalisib Increases Progression-Free Survival in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia
- BBD Regimen Efficacious as First-line Therapy for Myeloma
- Some Early Breast Cancer Patients Should Have Breast Conservation Instead of Mastectomy
- Trends in Behaviors, Medical Practice Indicate Mortality From Melanoma Will Decline
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Nut Consumption Inversely Associated With Lung Cancer Risk
- Targeting AR Mutations Promising in Metastatic Prostate Cancer
- GUCS 2017: Early Immunotherapy Discontinuation in mRCC
- Pembrolizumab Active Against Rare Melanoma, Extends Survival in Bladder Cancer
- Myalgia-arthralgia Syndrome Associated With Taxanes in Patients with Breast Cancer
- Women Treated for DCIS Have Slightly Lower Risk for All-Cause Mortality
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|